Identification of potential therapeutic targets for colorectal cancer by bioinformatics analysis

Ming Yan1, Maomin Song1, Rixing Bai1

  • 1Department of General Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, P.R. China.

Oncology Letters
|January 21, 2017
PubMed

Insights

This study identified 1,347 differentially expressed genes in colorectal cancer (CRC), many linked to cell cycle regulation. Key genes like CDK1 and MYC emerged as potential therapeutic targets for CRC treatment.

Area of Science:

  • Genomics
  • Oncology
  • Bioinformatics

Background:

  • Colorectal cancer (CRC) remains a significant global health challenge.
  • Identifying novel therapeutic targets is crucial for improving CRC patient outcomes.

Purpose of the Study:

  • To identify potential therapeutic targets for colorectal cancer (CRC).
  • To analyze differentially expressed genes (DEGs) and their associated pathways in CRC tissues.

Main Methods:

  • Utilized gene expression profile GSE32323 from the Gene Expression Omnibus database.
  • Applied bioinformatics tools for data preprocessing, DEG identification, functional enrichment, and network analysis (PPI, miRNA-target).

Main Results:

  • Identified 1,347 DEGs, predominantly enriched in cell cycle pathways.
  • Highlighted key genes (CDK1, CCNB1, MAD2L1, BUB1B) in the protein-protein interaction network.
  • Discovered SOX4, MYC, and CCND1 as significant targets in the miRNA-target network, with potential roles in the p53 signaling pathway.

Conclusions:

  • Several cell cycle and p53 pathway-associated genes identified as potential biomarkers for CRC.
  • CDK1, CCNB1, MAD2L1, BUB1B, SOX4, collagen type I α2 chain, and MYC may significantly influence CRC progression.
  • CDK1, CCNB1, and CCND1 show potential as crucial regulators in the p53 signaling pathway.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K